Online citations, reference lists, and bibliographies.

Hexaminolevulinate Hydrochloride In The Detection Of Nonmuscle Invasive Cancer Of The Bladder

Savino M. Di Stasi, Francesco De Carlo, Vincenzo Pagliarulo, Francesco Masedu, Cristian Verri, Francesco Celestino, Claus Riedl
Published 2015 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Clinical trials have shown that hexaminolevulinate (HAL) fluorescence cystoscopy improves the detection of bladder tumors compared with standard white-light cystoscopy, resulting in more efficacious treatment. However, some recent meta-analyses report controversially on recurrence-free rates with this procedure. A systematic review of literature was performed from December 2014 to January 2015 using the PubMed, Embase and Cochrane databases for controlled trials on photodynamic diagnosis (PDD) with HAL. A total of 154 publications were found up to January 2015. Three of the authors separately reviewed the records to evaluate eligibility and methodological quality of clinical trials. A total of 16 publications were considered eligible for analysis. HAL–PDD-guided cystoscopy increased overall tumor detection rate (proportion difference 19%, 95% confidence interval [CI] 0.152–0.236) although the benefit was particularly significant in patients with carcinoma in situ (CIS) lesion (proportion difference 15.7%, 95% CI 0.069–0.245) and was reduced in papillary lesions (Ta proportion difference 5.9%, 95% CI 0.014–0.103 and T1 proportion difference 1.2%, 95% CI 0.033–0.057). Moreover, there were 15% of patients (95% CI 0.098–0.211) with at least one additional tumor seen with PDD. With regard to recurrence rates, the data sample was insufficient for a statistical analysis, although the evaluation of raw data showed a trend in favor of HAL–PDD. This meta-analysis confirms the increased tumor detection rate by HAL–PDD with a most pronounced benefit for CIS lesion.
This paper references
10.1097/01.ju.0000169257.19841.2a
Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study.
Dieter Jocham (2005)
10.1016/j.urology.2005.02.003
Correlation of office-based cystoscopy and cytology with histologic diagnosis: how good is the reference standard?
Robert Scott Svatek (2005)
10.1136/bmj.327.7414.557
Measuring inconsistency in meta-analyses
Julian P. T. Higgins (2003)
10.1016/j.juro.2009.06.039
Optical biopsy of human bladder neoplasia with in vivo confocal laser endomicroscopy.
Geoffrey A. Sonn (2009)
10.1177/0091270006286849
Determination of the bioavailability of [14C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers.
Bernie Klem (2006)
10.1016/j.juro.2007.03.034
A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.
Herbert Barton Grossman (2007)
10.1016/J.ACUROE.2011.03.006
Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer: experience of the BLUE group
Juan Pablo Burgués (2011)
10.1016/j.urology.2010.02.067
HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer--re-TURBT recurrence rates in a prospective, randomized study.
Bogdan Florin Geavlete (2010)
TURBT recurrence rates in a prospective, randomized study. Urology
B. Geavlete (2011)
10.3109/00365599.2011.633279
Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance
P U Malmström (2012)
10.1016/j.eururo.2010.01.025
Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations.
Johannes Alfred Witjes (2010)
Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection
T. O’Brien (2013)
10.1111/j.1464-410X.2011.10374.x
Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Bogdan Florin Geavlete (2012)
10.1364/OE.18.003840
Time- and Spectral-resolved two-photon imaging of healthy bladder mucosa and carcinoma in situ.
Riccardo Cicchi (2010)
10.1016/S1470-2045(11)70190-5
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Savino M Di Stasi (2011)
10.1016/j.urology.2009.11.075
Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer.
Evelyne C. C. Cauberg (2010)
10.1016/j.urology.2012.03.067
Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences?
Theocharis Karaolides (2012)
Determination of the bioavailability
B. Klem (2006)
10.1097/01.ju.0000075054.38441.2d
Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer.
Alexandre Marti (2003)
BCG and electromotive mitomycin C versus BCG alone for high risk superficial bladder cancer: a randomised controlled trial
S. Stasi (2011)
Fluorescenceguided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients
G. Hermann (2011)
10.1117/1.2978059
High-resolution imaging diagnosis and staging of bladder cancer: comparison between optical coherence tomography and high-frequency ultrasound.
Zhijia Yuan (2008)
10.1364/BOE.2.000915
Label-free high-resolution imaging of prostate glands and cavernous nerves using coherent anti-Stokes Raman scattering microscopy
Liang Gao (2011)
HAL bluelight cystoscopy in high - risk nonmuscle - invasive bladder cancer – re - TURBT recurrence rates in a prospective , randomized study
B. Geavlete (2010)
10.1111/bju.12355
Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
Timothy O'Brien (2013)
10.1016/S0090-4295(94)80167-3
Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid.
Martin Kriegmair (1994)
10.1136/bmj.315.7109.629
Bias in meta-analysis detected by a simple, graphical test
Matthias Egger (1997)
* Photodynamic Diagnosis in Non-Muscle-Invasive Bladder Cancer : A Systematic Review and Cumulative Analysis of Prospective Studies
Hopital Cantonal (2010)
Novel endoscopic diagnosis for bladder
T. Lin (2015)
imaging of prostate glands and cavernous nerves using coherent anti-Stokes Raman scattering microscopy
K. Berg (1997)
10.1111/j.1751-1097.1997.tb08549.x
5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research.
Qian Peng (1997)
10.1007/s00464-012-2387-0
A comparison of hexaminolevulinate (Hexvix®) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study
Alberto Lapini (2012)
10.1097/01.ju.0000100480.70769.0e
Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy.
Jörg Schmidbauer (2004)
10.1098/rstl.1852.0022
XXX. On the change of refrangibility of light
George Gabriel Sir Stokes (1852)
10.1111/j.1751-1097.2009.00543.x
siRNA-mediated knockdown of the heme synthesis and degradation pathways: modulation of treatment effect of 5-aminolevulinic acid-based photodynamic therapy in urothelial cancer cell lines.
Makito Miyake (2009)
10.1007/s11255-013-0603-z
Hexaminolevulinate-guided transurethral resection of non-muscle-invasive bladder cancer does not reduce the recurrence rates after a 2-year follow-up: a prospective randomized trial
Pavlos Gkritsios (2013)
Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture.
J. M. Gaullier (1997)
10.1016/j.urology.2008.02.002
Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer.
Alvin C. Goh (2007)
10.1017/S0266462310001364
Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis.
Graham Mowatt (2011)
10.1089/end.2005.19.570
Evaluation of superficial bladder transitional-cell carcinoma by optical coherence tomography.
Michael J. Manyak (2005)
10.1111/j.1464-410X.2011.10485.x
The sensitivity of fluorescent-light cystoscopy for the detection of carcinoma in situ (CIS) of the bladder: a meta-analysis with comments on gold standard.
Björn L Isfoss (2011)
10.1016/j.juro.2010.06.148
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.
Arnulf Stenzl (2010)
10.1089/end.2008.0642
Hexylaminolevulinate photodynamic diagnosis for multifocal recurrent nonmuscle invasive bladder cancer.
Eleanor R. Ray (2009)
10.1002/cncr.28905
Novel endoscopic diagnosis for bladder cancer.
Seth P. Lerner (2015)
10.1097/01.ju.0000060782.52358.04
Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study.
Patrice Jichlinski (2003)
10.1111/j.1442-2042.2012.03211.x
Diagnosis of narrow-band imaging in non-muscle-invasive bladder cancer: a systematic review and meta-analysis.
Kai-wen Li (2013)
10.1016/S1470-2045(05)70472-1
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
Savino M Di Stasi (2006)
10.1016/j.juro.2012.03.127
New optical imaging technologies for bladder cancer: considerations and perspectives.
Jen‐Jane Liu (2012)
10.1007/s00280-010-1375-0
Biodistribution of PVP-hypericin and hexaminolevulinate-induced PpIX in normal and orthotopic tumor-bearing rat urinary bladder
Joachim Vandepitte (2010)
10.1002/jbio.201200105
Combined use of fluorescence cystoscopy and cross-polarization OCT for diagnosis of bladder cancer and correlation with immunohistochemical markers.
Natalia D Gladkova (2013)
10.1111/j.1751-1097.1998.tb02521.x
In vivo fluorescence spectroscopy and imaging for oncological applications.
Georges Wagnières (1998)
Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies.
Savino M Di Stasi (1999)
siRNAmediated knockdown of the heme synthesis and degradation pathways: modulation of treatment effect of 5-aminolevulinic acid-based photodynamic therapy in urothelial cancer cell lines
K. Sugano (2009)
10.1111/j.1464-410X.2011.10090.x
Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study.
Gregers Gautier Hermann (2011)
10.1016/j.eururo.2014.06.049
Randomized trial of narrow-band versus white-light cystoscopy for restaging (second-look) transurethral resection of bladder tumors.
Harry W. Herr (2015)
10.1017/CBO9780511702266.011
Mathematical and Physical Papers: Abstract of a paper “On the Change of Refrangibility of Light”
George Gabriel Sir Stokes (2009)
10.1111/j.1464-410X.2008.07966.x
Quality control in transurethral resection of bladder tumours.
Harry W Herr (2008)
10.1016/j.pdpdt.2008.05.001
The economic benefit of photodynamic diagnosis in non-muscle invasive bladder cancer.
Sanjay Dindyal (2008)
10.1016/j.eururo.2013.06.003
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Marko Babjuk (2013)
10.1016/j.eururo.2014.01.006
The economics of bladder cancer: costs and considerations of caring for this disease.
Robert Scott Svatek (2014)
10.1016/j.juro.2007.09.003
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.
Matthew C. Hall (2007)
10.1016/j.juro.2007.03.028
A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study.
Yves Fradet (2007)
Photodynamic diagnosis of non-muscle invasive bladder cancer using hexaminolevulinic acid.
Octavian Drăgoescu (2011)
IARC CancerBase No. 11. Lyon, France: International Agency for Research
Y. Cancer. Fradet (2007)
High - resolution imaging diagnosis and staging of bladder cancer : comparison between optical coherence tomography and high - frequency ultrasound [ serial online ]
D. Zlatev (2015)
10.1111/j.1464-410X.2010.09547.x
Reduced bladder tumour recurrence rate associated with narrow-band imaging surveillance cystoscopy.
Harry W. Herr (2011)
10.1016/j.ucl.2015.01.001
Advances in imaging technologies in the evaluation of high-grade bladder cancer.
Dimitar V Zlatev (2015)
10.1016/j.eururo.2005.12.031
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.
Richard J. Sylvester (2006)



This paper is referenced by
Benign Prostatic Enlargement Emerging treatments challenge standard approaches Expert challenges expert Activating patients is key to enhanced recovery Plenary Session 3 : Redefining contemporary bladder cancer care
hird Eition (2017)
10.4172/2168-9857.1000180
Efficacy of Hexaminolevulinate Photodynamic Diagnosis of Non-Muscle Invasive Bladder Cancer
Ioannis Papazoglou (2017)
Blue Light Cystoscopy in Patients with Suspected Non-Muscle Invasive BladderCarcinoma: A Review of Clinical Utility
Kira Tran (2017)
10.1007/s11934-017-0685-8
The Impact of Blue Light Cystoscopy on the Diagnosis and Treatment of Bladder Cancer
Eugene J. Pietzak (2017)
10.1007/S40267-017-0436-4
Hexaminolevulinate: a profile of its use with blue-light cystoscopy in the diagnosis of bladder cancer
Katherine A. Lyseng-Williamson (2017)
10.1089/end.2016.0804
Diagnostic Accuracy of Hexaminolevulinate in a Cohort of Patients Undergoing Radical Cystectomy.
Vincenzo Pagliarulo (2017)
Improved diagnosis and long-term recurrence rate reduction for non-muscle-invasive bladder cancer patients undergoing fluorescent hexylaminolevulinate photodynamic diagnosis.
Petru Octavian Drăgoescu (2017)
10.1364/josaa.36.000c62
Clinical evaluation of a device providing simultaneous white-light and fluorescence video streams as well as panoramic imaging during fluorescence assisted-transurethral resection of bladder cancer.
Marine Amouroux (2019)
10.1089/END.2016.0804
Diagnostic Accuracy of Hexaminolevulinate in a Cohort of Patients Undergoing Radical Cystectomy.
PagliaruloVincenzo (2017)
Semantic Scholar Logo Some data provided by SemanticScholar